Delta-Fly Pharma (TYO:4598) said it has submitted all data needed for an interim analysis of its Phase 3 study of DFP-10917 in relapsed or refractory acute myeloid leukemia patients in the US to the Data Safety Management Board, according to a Monday filing on the Tokyo Stock Exchange.
The company said an expanded study of DFP-14927 in pancreatic cancer after Gemcitabine/nab-PTX failure will target a disease control rate of more than 25% at MD Anderson Cancer Center.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.